These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 15297055)

  • 1. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
    J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P; Saxena S; Madhubala R
    Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome.
    Jaafari MR; Badiee A; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
    Vaccine; 2007 Aug; 25(32):6107-17. PubMed ID: 17629372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
    Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
    Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
    Datta N; Mukherjee S; Das L; Das PK
    Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection.
    Sánchez VR; Pitkowski MN; Fernández Cuppari AV; Rodríguez FM; Fenoy IM; Frank FM; Goldman A; Corral RS; Martin V
    Exp Parasitol; 2011 Aug; 128(4):448-53. PubMed ID: 21554876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T; Anam K; Ali N
    Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii.
    Saavedra R; Leyva R; Tenorio EP; Haces ML; Rodríguez-Sosa M; Terrazas LI; Hérion P
    Parasite Immunol; 2004 Feb; 26(2):67-73. PubMed ID: 15225293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
    Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
    Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
    Mazumder S; Ravindran R; Banerjee A; Ali N
    Vaccine; 2007 Dec; 25(52):8771-81. PubMed ID: 18031874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
    Bhardwaj S; Vasishta RK; Arora SK
    Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmaniasis: current status of vaccine development.
    Sukumaran B; Madhubala R
    Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
    Kwant A; Rosenthal KL
    Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.